https://www.neurologylive.com/view/ms-treatment-temelimab-gnbac1-shows-sustained-96week-efficacy
MS Treatment Temelimab (GNbAC1) Shows Sustained 96-Week Efficacy | NeurologyLive - Clinical...
Oct 14, 2026 - The GeNeuro agent showed marked reductions in brain atrophy in the thalamus and cerebral cortex through a long-term extension period treating patients with...
ms treatmenttemelimabshowssustainedweek